Injectable Medication | Page 5 of 10

FDA Approves Byetta for Use with Lantus Insulin in the U.S.

The U.S. Food and Drug Administration (FDA) has approved a new use for Amylin and Eli Lilly's type 2 diabetes drug, Byetta (exenatide) injection. Byetta is now approved as an add-on therapy to insulin glargine (Lantus), with or without metformin and/or a thiazolidinedione (TZD), for adults with type 2 diabetes...

Victoza, Novo Nordisk’s Type 2 Diabetes Drug, Available in China

Victoza, Novo Nordisks best selling type 2 diabetes drug is now commercially available in China. Victoza, (liraglutide injection), the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analog, was approved for type 2 diabetes by the Chinese State Food and Drug Administration in March 2011...

Eu Adopts Positive Opinion on Levemir as an Add-On Therapy to Victoza in Type 2 Diabetes Patients

Following a review of new data from a 52-week clinical trial, the European Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on the usage of Novo Nordisk’s basal insulin analogue, Levemir, as add-on therapy to Novo Nordisk’s GLP-1 analogue, Victoza, in combination with metformin in patients with type 2 diabetes...

Victoza: The Earlier The Better, New Study Shows

New data presented at the European Association for the Study of Diabetes (EASD) shows a significantly higher proportion of patients reached target HbA1c levels of <7% when Victoza (liraglutide [rDNA origin] injection) was administrated early in the treatment of type 2 diabetes to patients who had not received treatment before or had previously received only one oral anti-diabetic drug (OAD)...

Type 2 Drug Bydureon Proves More Effective Than Other Common Diabetes Treatments

Amylin Pharmaceuticals, Eli Lilly and Alkermes announced new analyses from the DURATION-3 and DURATION-4 trials demonstrating patients treated with the investigational medication Bydureon (exenatide extended-release for injectable suspension) experienced significant improvements in select cardiovascular risk factors, in comparison to patients who received commonly prescribed diabetes treatments...

GlucaPen: The Way Glucagon Ought To Be

The current glucagon kits are not user-friendly, to say the least...

Why Victoza Matters

Why bother adding Victoza to an already lengthy list of treatments for type 2 diabetes? Is marginal improvement in a clinical trial enough to warrant educating physicians and patients about yet another option?

Victoza Found More Effective Than Byetta and Januvia In Treatment of Type 2 Diabetes

New data from two extension studies presented by Novo Nordisk at the 71st Annual Scientific Sessions of the American Diabetes Association (ADA) show that Victoza (liraglutide [rDNA origin] injection), taken once-daily, in combination with metformin and/or sulfonylurea, helped patients achieve blood sugar control after switching from other commonly used type 2 diabetes therapies Byetta (exenatide) and Januvia (sitagliptin). Although not..

Insulin Pump Users Benefit from Symlin

New data from two previously completed clinical studies show that Symlin (pramlintide acetate) helped reduce A1c levels, insulin use and body weight in patients with type 1 diabetes who used insulin pumps. The data was presented by Amylin Pharmaceuticals during...

Adding Byetta to Diabetes Treatment May Reduce Risk Of Heart Failure

Results from a retrospective analysis of more than 778,000 patients showed the addition of Byetta (exenatide) injection to pre-existing diabetes treatment regimens was associated with a reduced likelihood of heart failure, especially among patients receiving insulin. These findings were presented by Amylin and Eli Lilly...